An analysis of genetic biomarkers from Genetic Engineering & Biotechnology explains the differences between predictive and prognostic characteristics and provides a perspective on the current landscape of research and development for a number of key assays.

Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.

Lasers that can flip cells off and on and brain scanners that can be worn are just two projects receiving federal grants as a part of the $100 million BRAIN Initiative aimed to learn more about the inner-workings of the brain.

Lower amounts of a protein called progranulin in the brain have been shown to increase beta-amyloid formation and neuroinflammation. A gene therapy may be the key to reversing these markers of Alzheimer’s disease, Gladstone Institutes announced yesterday.

BioClinica, Inc., a leading provider of outsourced clinical trial services and eClinical Solutions, today announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award.

Following World Alzheimer's Day, a list of recent Alzheimer's studies, including brain PET research, was recently published by Examiner.com.

Acorda Therapeutics has made an agreement with Civitas Therapeutics to acquire the latter for $525 million. The purchase comes with global rights over a portfolio of drugs in development, including an inhalable drug called CVT-301, currently being validated for the treatment of Parkinson’s disease symptoms, Acorda announced Sept. 24.

Navidea Biopharmaceuticals announced Friday that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), is recommending marketing authorization in the European Union for Lymphoseek (tilmanocept) preparation for the presurgical mapping of sentinel lymph nodes that provide a point of potential metastasis in primary head and beck oral cavity squamous cell carcinoma, melanoma and breast cancer.